BRÈVE

sur BIOSYNEX (EPA:ALBIO)

BIOSYNEX strengthens its governance and promotes new talents

Graphique de l'évolution du cours de l'action BIOSYNEX (EPA:ALBIO).

BIOSYNEX, a major player in health diagnostics, today announced the promotion of Oren Bitton to the position of Group Deputy Managing Director. Joining the company in 2011, Oren Bitton previously led the Pharma Business Unit since September 2022, where he led the development of the business and the post-Covid transition. In his new role, he is responsible for meeting the growth and profitability objectives of the TRANSFORM 2025 plan. He will work under the leadership of Larry Abensur, President and Founder, and will be supported by other co-founders for various strategic areas.

The Board of Directors of BIOSYNEX also proposed the appointment of two directors, including Brigitte Geny as independent director, and Diane Abensur. Brigitte Geny brings her expertise of more than 25 years in auditing, while Diane Abensur brings her experience as an entrepreneur in the field of medical technologies. These appointments aim to strengthen the company's governance expertise, particularly in the healthcare sector and environmental, social and governance (ESG) issues.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de BIOSYNEX